These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 7041107)

  • 1. [Graft-versus-host disease (author's transl)].
    Gratwohl A
    Schweiz Rundsch Med Prax; 1982 Jan; 71(4):129-31. PubMed ID: 7041107
    [No Abstract]   [Full Text] [Related]  

  • 2. Decreased incidence and severity of graft-versus-host disease in HLA matched and mismatched marrow recipients of cyclosporine and methotrexate.
    Tollemar J; Ringdén O; Heimdahl A; Lönnqvist B; Sundberg B
    Transplant Proc; 1988 Jun; 20(3 Suppl 3):470-9. PubMed ID: 3291283
    [No Abstract]   [Full Text] [Related]  

  • 3. Syngeneic graft-versus-host disease after allogeneic bone marrow transplantation and cyclosporine treatment.
    Hess AD; Vogelsang GB; Silanskis M; Friedman KA; Beschorner WE; Santos GW
    Transplant Proc; 1988 Jun; 20(3 Suppl 3):487-92. PubMed ID: 3291285
    [No Abstract]   [Full Text] [Related]  

  • 4. Use of cyclosporine for prevention of graft-versus-host disease after allogeneic bone marrow transplantation.
    Gluckman E; Devergie A; Lokiec F
    Transplant Proc; 1988 Jun; 20(3 Suppl 3):461-9. PubMed ID: 3291282
    [No Abstract]   [Full Text] [Related]  

  • 5. Cyclosporin A: use in preventing graft versus host disease.
    Klemm P
    Oncol Nurs Forum; 1985; 12(5):25-32. PubMed ID: 3898028
    [No Abstract]   [Full Text] [Related]  

  • 6. Omission of day 11 methotrexate does not appear to influence the incidence of moderate to severe acute graft-versus-host disease, chronic graft-versus-host disease, relapse rate or survival after HLA-identical sibling bone marrow transplantation.
    Atkinson K; Downs K
    Bone Marrow Transplant; 1995 Dec; 16(6):755-8. PubMed ID: 8750265
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Graft versus host disease: the most threatening complication of bone marrow transplant. Review of the literature].
    Rasero L; Bonavita K; Marsullo M
    Assist Inferm Ric; 2002; 21(4):211-21. PubMed ID: 12674033
    [No Abstract]   [Full Text] [Related]  

  • 8. Helper T-lymphocyte precursor frequencies predict risks of graft-versus-host disease in bone marrow transplantation.
    Batchelor JR; Schwarer AP; Yin ZJ; Barrett AJ; Goldman JM; Lechler RI
    Transplant Proc; 1993 Feb; 25(1 Pt 2):1237-8. PubMed ID: 8442100
    [No Abstract]   [Full Text] [Related]  

  • 9. Cross species graft-versus-host disease induces hepatic injury in association with a donor-derived cellular immune response.
    Cooper MH; Nalesnik MA; Watkins SC; Schachter MJ; Ildstad ST
    Transplant Proc; 1993 Feb; 25(1 Pt 2):1283. PubMed ID: 8442113
    [No Abstract]   [Full Text] [Related]  

  • 10. T cell immunity and graft-versus-host disease (GVHD).
    Ichiki Y; Bowlus CL; Shimoda S; Ishibashi H; Vierling JM; Gershwin ME
    Autoimmun Rev; 2006 Jan; 5(1):1-9. PubMed ID: 16338205
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bone marrow transplantation with ciclosporin.
    Gratwohl A; Speck B
    Prog Allergy; 1986; 38():404-31. PubMed ID: 3523495
    [No Abstract]   [Full Text] [Related]  

  • 12. Bone marrow transplantation from genetically HLA-nonidentical donors in children with fatal inherited disorders excluding severe combined immunodeficiencies: use of two monoclonal antibodies to prevent graft rejection.
    Jabado N; Le Deist F; Cant A; De Graeff-Meeders ER; Fasth A; Morgan G; Vellodi A; Hale G; Bujan W; Thomas C; Cavazzana-Calvo M; Wijdenes J; Fischer A
    Pediatrics; 1996 Sep; 98(3 Pt 1):420-8. PubMed ID: 8784367
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune reconstitution post-bone marrow transplantation.
    Gelfand EW
    Int J Cell Cloning; 1986; 4 Suppl 1():19-25. PubMed ID: 3528331
    [No Abstract]   [Full Text] [Related]  

  • 14. Impact of AB0-blood group incompatibility on the outcome of recipients of bone marrow transplants from unrelated donors in the Japan Marrow Donor Program.
    Kimura F; Sato K; Kobayashi S; Ikeda T; Sao H; Okamoto S; Miyamura K; Mori S; Akiyama H; Hirokawa M; Ohto H; Ashida H; Motoyoshi K;
    Haematologica; 2008 Nov; 93(11):1686-93. PubMed ID: 18835834
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Frequency analysis of cytotoxic T lymphocyte precursors in search for donors in bone marrow transplantation.
    Cukrová V; Dolezalová L; Loudová M; Matĕjková E; Korínková P; Lukásová M; Starý J
    Neoplasma; 1995; 42(1):3-8. PubMed ID: 7617071
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevention of graft-versus-host disease on an individual basis.
    Aschan J; Ringdén O; Andström E; Ljungman P; Remberger M
    Transplant Proc; 1994 Jun; 26(3):1823-4. PubMed ID: 8030155
    [No Abstract]   [Full Text] [Related]  

  • 17. Major histocompatibility complex influences the development of acute graft-versus-host disease in MHC-matched adult allogeneic bone marrow transplantation.
    Smyth LA; Herrmann RP; Christiansen FT; Hollingsworth PN; Townend DC; Edward E; Dawkins RL
    Transplant Proc; 1993 Feb; 25(1 Pt 2):1276-8. PubMed ID: 8442111
    [No Abstract]   [Full Text] [Related]  

  • 18. [Assessment of secondary disease based on HLA expression in the plasma of an allogeneic bone marrow recipient].
    Zotnikov EA; Vasiĺeva MN; Poreshina LP; Kutina RM; Golovkina LL; Liubimov LS; Mendeleeva LP; Savchenko VG
    Biull Eksp Biol Med; 1995 Dec; 120(12):596-8. PubMed ID: 8834210
    [No Abstract]   [Full Text] [Related]  

  • 19. Predictors of acute graft-versus-host disease in bone marrow transplantation between HLA-identical siblings.
    Johnsen HE
    N Engl J Med; 1993 May; 328(20):1497-8. PubMed ID: 8479479
    [No Abstract]   [Full Text] [Related]  

  • 20. Ciclosporin. Forward.
    Bernard J
    Prog Allergy; 1986; 38():1-8. PubMed ID: 3523490
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.